# Berberine as Adjuvant Treatment for Schizophrenia Patients

> **NCT02983188** · PHASE2,PHASE3 · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 113 (actual)

## Conditions studied

- Schizophrenia
- Schizophrenia Spectrum and Other Psychotic Disorders
- Metabolic Syndrome x

## Interventions

- **DRUG:** Berberine
- **DRUG:** Placebos
- **DRUG:** Antipsychotic Agents

## Key facts

- **NCT ID:** NCT02983188
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-25
- **Primary completion:** 2020-12-30
- **Final completion:** 2021-01-04
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2021-01-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02983188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02983188, "Berberine as Adjuvant Treatment for Schizophrenia Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02983188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*